Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan, Cyclophosphamide, and Filgrastim with Peripheral Stem Cell Transplantation for Hematologic Malignancies
NCT00003116Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 1997
- Primary completion
- Mar 2006
- Modality
- Stem Cell Therapies, Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic peripheral blood progenitor cells, busulfan, cyclophosphamide, filgrastim, cyclosporine in hematologic malignancy, leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), sponsored by Case Comprehensive Cancer Center. Started May 1997; status: completed.
02
Drugs
allogeneic peripheral blood progenitor cellsbusulfancyclophosphamidefilgrastimcyclosporine
03
Conditions
hematologic malignancyleukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003116.